. Author manuscript; available in PMC: 2009 Oct 5.

Published in final edited form as: Bone Marrow Transplant. 2008 Oct 13;43(5):417–422. doi: 10.1038/bmt.2008.334

Table 2.

Salvage auto-SCT clinical characteristics and response

Variable	Number (range or percent) or median (range) (n = 41)
Age at second auto-SCT	54 years (28–73)
Cytogenetics
Any result	25 (61%)
Abnormal result	9 (22%)
Time from first to second auto-SCT	37 months (3–91)
Number of prior lines of therapy	3 (1–10)
Specific therapies prior to second auto-SCT
Prior thalidomide	19 (46%)
Prior lenalidomide	9 (22%)
Prior bortezomib	24 (59%)
Responding disease prior to auto-SCT	15 (37%)
Conditioning
Melphalan 200 mg/m²	12 (29%)
Reduced dose melphalan	11 (27%)
Melphalan/TBI	14 (34%)
BU/CY	3 (7%)
CY/TBI	1 (2%)
Response
CR	2 (5%)
VGPR	4 (10%)
PR	15 (37%)
SD	11 (27%)
PD	6 (15%)
Could not be assessed	3 (7%)
Treatment-related mortality	3 (7%)

Abbreviations: PD = progressive disease; PR = partial response; SD = stable disease; VGPR = very good partial response.